Analyst Ratings For Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
Today, Piper Jaffray Companies reiterated its Overweight rating on Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) with a price target of $33.00.
There are 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is Buy with a consensus target price of $22.6967 per share, a potential 21.70% upside.
Some recent analyst ratings include
- 4/16/2019-Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) had its Overweight rating reiterated by Piper Jaffray Companies with a $33.00 price target
- 2/11/2019-Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) had its Buy rating reiterated by Chardan Capital with a $24.50 price target
- 10/17/2018-Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) had its Outperform rating reiterated by William Blair
- 9/6/2018-Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) gets upgraded to Buy by B. Riley with a price target of $19.00
- On 4/3/2019 Christopher Richard Anzalone, CEO, sold 50,000 with an average share price of $19.30 per share and the total transaction amounting to $965,000.00.
- On 3/1/2019 Bruce D Given, COO, sold 42,500 with an average share price of $19.99 per share and the total transaction amounting to $849,575.00.
- On 2/26/2019 Douglas B Given, Director, sold 65,000 with an average share price of $19.25 per share and the total transaction amounting to $1,251,250.00.
- On 2/25/2019 Bruce D Given, COO, sold 42,500 with an average share price of $18.98 per share and the total transaction amounting to $806,650.00.
- On 2/22/2019 Douglas B Given, Director, sold 3,000 with an average share price of $18.05 per share and the total transaction amounting to $54,150.00.
- On 2/19/2019 Bruce D Given, COO, sold 68,750 with an average share price of $17.86 per share and the total transaction amounting to $1,227,875.00.
- On 2/19/2019 Kenneth Allen Myszkowski, CFO, sold 8,000 with an average share price of $18.00 per share and the total transaction amounting to $144,000.00.
About Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Recent Trading Activity for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
Shares of Arrowhead Pharmaceuticals Inc closed the previous trading session at 18,65 +0,33 1,80 % with 1149000 shares trading hands.
